Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
152.55
+4.26 (2.87%)
Aug 12, 2026, 11:48 AM EDT - Market open
Protagonist Therapeutics Employees
Protagonist Therapeutics had 141 employees as of June 30, 2026. The number of employees increased by 11 or 8.46% compared to the same quarter last year.
Employees
141
Change
11
Growth
8.46%
Revenue / Employee
$1,999,943
Profits / Employee
$588,007
Market Cap
9.87B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 141 | 11 | 8.46% |
| Mar 31, 2026 | 131 | 7 | 5.65% |
| Dec 31, 2025 | 132 | 6 | 4.76% |
| Sep 30, 2025 | 128 | 2 | 1.59% |
| Jun 30, 2025 | 130 | 5 | 4.00% |
| Mar 31, 2025 | 124 | 0 | - |
| Dec 31, 2024 | 126 | 14 | 12.50% |
| Sep 30, 2024 | 126 | 15 | 13.51% |
| Jun 30, 2024 | 125 | 19 | 17.92% |
| Mar 31, 2024 | 124 | 21 | 20.39% |
| Dec 31, 2023 | 112 | 7 | 6.67% |
| Sep 30, 2023 | 111 | -11 | -9.02% |
| Jun 30, 2023 | 106 | -21 | -16.54% |
| Mar 31, 2023 | 103 | -19 | -15.57% |
| Dec 31, 2022 | 105 | -13 | -11.02% |
| Sep 30, 2022 | 122 | 6 | 5.17% |
| Jun 30, 2022 | 127 | 26 | 25.74% |
| Mar 31, 2022 | 122 | 39 | 46.99% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Ionis Pharmaceuticals | 1,480 |
| Cytokinetics | 673 |
| Crinetics Pharmaceuticals | 594 |
| Vaxcyte | 507 |
| Immunovant | 315 |
| Krystal Biotech | 295 |
| Apogee Therapeutics | 261 |
PTGX News
- 2 days ago - Protagonist Therapeutics price target raised to $170 from $145 at Truist - TheFly
- 2 days ago - Protagonist Therapeutics price target raised to $173 from $118 at Wedbush - TheFly
- 2 days ago - Protagonist Therapeutics upgraded to Buy from Neutral at Goldman Sachs - TheFly
- 6 days ago - Protagonist Therapeutics price target raised to $175 from $130 at Citi - TheFly
- 6 days ago - Protagonist Therapeutics price target raised to $173 from $116 at Clear Street - TheFly
- 6 days ago - Protagonist Therapeutics price target raised to $153 from $151 at Barclays - TheFly
- 6 days ago - Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93 - TheFly
- 6 days ago - Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Accesswire